New drug targets inflammation in Hard-to-Treat Behçet's disease
NCT ID NCT07634848
First seen Jun 27, 2026 · Last updated Jul 10, 2026 · Updated 1 time
Summary
This trial tests a drug called ivarmacitinib in people with Behçet's disease who have not improved with standard treatments. Ivarmacitinib blocks a key inflammation pathway (JAK-STAT) to reduce symptoms. Participants take the drug daily for 24 weeks, and researchers monitor their response and safety.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Ivarmacitinib
- What this could lead to
- If successful, this could offer a new treatment option for people with Behçet's disease who do not respond to current therapies.
- What could go wrong
- This is a small, early-phase trial with only 30 participants and no comparison group. Results may not apply to all patients, and side effects are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BEHCET'S SYNDROME are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Department of Rheumatology and Immunology, Peking University People's Hospital
Beijing, Beijing Municipality, China